Developments of polo-like kinase 1 (Plk1) inhibitors as anti-cancer agents

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Polo-like kinases (Plks) are crucial serine/threonine kinases regulating cell cycle progression.
• Plk1 is a key mitotic regulator overexpressed in many cancers, making it a promising therapeutic target.
• Current Plk1 inhibitors primarily target the ATP-binding site or other regions.

Purpose of the Study:

• To review pre-clinical and clinical Plk1 inhibitors.
• To focus on structure-activity relationship (SAR) studies and biological activities.
• To evaluate in vitro and in vivo anti-tumor efficacy and combination therapy effects.

Main Methods:

• Review of existing literature on Plk1 inhibitors.
• Analysis of SAR studies for inhibitor design.
• Assessment of kinase activity, cellular effects, and in vivo efficacy.
• Evaluation of combination therapies with other anticancer agents.

Main Results:

• Numerous Plk1 inhibitors demonstrate significant therapeutic effects.
• Inhibitors exhibit potent kinase inhibition, in vitro anti-tumor activity, and in vivo efficacy.
• Combination therapies with Plk1 inhibitors yield synergistic anti-cancer effects.

Conclusions:

• Plk1 inhibitors represent a promising class of anti-cancer agents.
• SAR studies are vital for developing effective Plk1-targeted therapies.
• Combination strategies can enhance the therapeutic potential of Plk1 inhibitors in oncology.